Yu MM. Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2? World J Clin Infect Dis 2021; 11(3): 60-62 [DOI: 10.5495/wjcid.v11.i3.60]
Corresponding Author of This Article
Ming-Ming Yu, PhD, Doctor, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266100, Shandong Province, China. mingmingyu@bjmu.edu.cn
Research Domain of This Article
Infectious Diseases
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Nov 5, 2021 (publication date) through Oct 31, 2025
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Infectious Diseases
ISSN
2220-3176
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Yu MM. Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2? World J Clin Infect Dis 2021; 11(3): 60-62 [DOI: 10.5495/wjcid.v11.i3.60]
World J Clin Infect Dis. Nov 5, 2021; 11(3): 60-62 Published online Nov 5, 2021. doi: 10.5495/wjcid.v11.i3.60
Can a radioimmunoassay kit be developed for accurate detection of the S protein of severe acute respiratory syndrome coronavirus 2?
Ming-Ming Yu
Ming-Ming Yu, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao 266100, Shandong Province, China
Author contributions: Yu MM designed and wrote the letter.
Conflict-of-interest statement: Dr. Yu has nothing to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ming-Ming Yu, PhD, Doctor, Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, No. 59 Haier Road, Qingdao 266100, Shandong Province, China. mingmingyu@bjmu.edu.cn
Received: June 19, 2021 Peer-review started: June 19, 2021 First decision: July 31, 2021 Revised: August 18, 2021 Accepted: October 20, 2021 Article in press: October 20, 2021 Published online: November 5, 2021 Processing time: 136 Days and 1.6 Hours
Abstract
The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 spread worldwide within only a few months. The screening and timely isolation of infected individuals have been regarded as an effective means of epidemic prevention and control. Therefore, effective screening of infected individuals plays a vital role in epidemic prevention and control. At present, reverse transcription-polymerase chain reaction (RT–PCR) is the main method for the in vitro detection of SARS-CoV-2. However, RT–PCR requires certified laboratories, expensive equipment, and trained technicians. Therefore, it is necessary to develop simpler and more convenient methods. Some studies have shown that the PepKAA peptide has a high affinity for the S protein of SARS-CoV-2. The tyrosine in PepKAA is labeled with 125I and used to design a radioimmunoassay kit for the detection of the S protein of SARS-CoV-2, which is of great significance for the early diagnosis of COVID-19.
Core Tip: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is highly infectious, and early detection of SARS-CoV-2 is the key factor in preventing another epidemic. Radioimmunoassay (RIA) exhibits high sensitivity and specificity. The detection of the S protein on the surface of SARS-CoV-2 by RIA is expected to be applied for the early diagnosis of coronavirus disease 2019, which may have a considerable impact on the control of the epidemic.
